0.438734 	 (+): Aryldialkylphosphatase  IC
0.438734 	 (+): Death, Sudden, Cardiac  O
0.438734 	 (+): Individuality
0.438734 	 (+): Prosthesis Design
0.438132 	 (+): Disease-Free Survival   O
0.438132 	 (+): Immunosuppressive Agents
0.438132 	 (+): Intracranial Aneurysm
0.438132 	 (+): Light
0.438132 	 (+): Paclitaxel
0.437534 	 (+): Adrenergic Agonists
0.437534 	 (+): Angina, Stable  P
0.437534 	 (+): Anterior Wall Myocardial Infarction P
0.437534 	 (+): Anti-Inflammatory Agents
0.437534 	 (+): Antineoplastic Agents, Phytogenic
0.437534 	 (+): Antiplatyhelmintic Agents
0.437534 	 (+): Atherosclerosis P
0.437534 	 (+): Automation
0.437534 	 (+): Basilar Artery
0.437534 	 (+): Biological Assay
0.437534 	 (+): California
0.437534 	 (+): Cause of Death
0.437534 	 (+): Cell Proliferation
0.437534 	 (+): Chromosomes, Human, Pair 10
0.437534 	 (+): Cineangiography
0.437534 	 (+): Codon, Nonsense
0.437534 	 (+): Cytokines
0.437534 	 (+): Cytosine
0.437534 	 (+): DNA Mutational Analysis
0.437534 	 (+): E-Selectin
0.437534 	 (+): Early Diagnosis
0.437534 	 (+): Endovascular Procedures P
0.437534 	 (+): England
0.437534 	 (+): Ethnic Groups
0.437534 	 (+): Europe
0.437534 	 (+): Genetic Markers
0.437534 	 (+): Genome-Wide Association Study
0.437534 	 (+): Heart
0.437534 	 (+): Heart Arrest    O
0.437534 	 (+): Heart Injuries
0.437534 	 (+): Hospitalization
0.437534 	 (+): Hypothermia, Induced
0.437534 	 (+): Immunoassay
0.437534 	 (+): Immunologic Factors
0.437534 	 (+): Intracranial Hemorrhages
0.437534 	 (+): Iron
0.437534 	 (+): Italy
0.437534 	 (+): Kidney Diseases
0.437534 	 (+): Kidney Function Tests
0.437534 	 (+): Likelihood Functions
0.437534 	 (+): Longitudinal Studies
0.437534 	 (+): Mass Spectrometry
0.437534 	 (+): Microsomes, Liver
0.437534 	 (+): Mitogen-Activated Protein Kinase 3
0.437534 	 (+): Mortality
0.437534 	 (+): Muscle, Smooth, Vascular
0.437534 	 (+): Oligonucleotide Array Sequence Analysis
0.437534 	 (+): Optical Rotation
0.437534 	 (+): Outpatients
0.437534 	 (+): Paris
0.437534 	 (+): Patient Discharge
0.437534 	 (+): Phosphodiesterase 3 Inhibitors
0.437534 	 (+): Placebo Effect
0.437534 	 (+): Preoperative Period
0.437534 	 (+): Protein Isoforms
0.437534 	 (+): Quinazolinones
0.437534 	 (+): Receptors, Purinergic P2Y2
0.437534 	 (+): Renal Insufficiency, Chronic
0.437534 	 (+): Reoperation
0.437534 	 (+): Sample Size
0.437534 	 (+): Social Adjustment
0.437534 	 (+): Stainless Steel
0.437534 	 (+): Substrate Specificity
0.437534 	 (+): Switzerland
0.437534 	 (+): Thromboxane A2
0.437534 	 (+): Thymine
0.437534 	 (+): Time
0.437534 	 (+): Tomography, Optical Coherence
0.437534 	 (+): Ventricular Function, Left
0.437534 	 (+): Vertebral Artery
0.437534 	 (+): Victoria
0.437534 	 (+): Whole Blood Coagulation Time    O
0.436695 	 (-): ADAM Proteins
0.436695 	 (-): Acetylcysteine
0.436695 	 (-): Adenine
0.436695 	 (-): Adrenergic beta-1 Receptor Antagonists
0.436695 	 (-): African Americans
0.436695 	 (-): Aging
0.436695 	 (-): Ambulatory Care
0.436695 	 (-): Amino Acid Chloromethyl Ketones
0.436695 	 (-): Amlodipine
0.436695 	 (-): Amputation
0.436695 	 (-): Anesthesia
0.436695 	 (-): Anesthesia, General
0.436695 	 (-): Aneurysm
0.436695 	 (-): Angiography
0.436695 	 (-): Angioplasty, Balloon, Laser-Assisted
0.436695 	 (-): Angiotensin-Converting Enzyme Inhibitors
0.436695 	 (-): Antidepressive Agents
0.436695 	 (-): Antifibrinolytic Agents
0.436695 	 (-): Antigens
0.436695 	 (-): Antigens, CD14
0.436695 	 (-): Antigens, CD151
0.436695 	 (-): Antigens, CD31
0.436695 	 (-): Antihypertensive Agents
0.436695 	 (-): Anxiety Disorders
0.436695 	 (-): Aortic Valve
0.436695 	 (-): Arteriosclerosis
0.436695 	 (-): Arteriovenous Shunt, Surgical
0.436695 	 (-): Asian Americans
0.436695 	 (-): Atenolol
0.436695 	 (-): Baltimore
0.436695 	 (-): Base Pairing
0.436695 	 (-): Binding Sites
0.436695 	 (-): Bisoprolol
0.436695 	 (-): Blood
0.436695 	 (-): Blood Donors
0.436695 	 (-): Blood Volume
0.436695 	 (-): Brachytherapy
0.436695 	 (-): Brain Diseases
0.436695 	 (-): CHO Cells
0.436695 	 (-): Caffeine
0.436695 	 (-): Calcinosis
0.436695 	 (-): Captopril
0.436695 	 (-): Carbon Isotopes
0.436695 	 (-): Cardiopulmonary Bypass
0.436695 	 (-): Carotid Arteries
0.436695 	 (-): Carotid Artery Diseases
0.436695 	 (-): Catecholamines
0.436695 	 (-): Catheterization, Peripheral
0.436695 	 (-): Cell Communication
0.436695 	 (-): Cell Count
0.436695 	 (-): Cell Degranulation
0.436695 	 (-): Cell Membrane
0.436695 	 (-): Cell Separation
0.436695 	 (-): Cell Shape
0.436695 	 (-): Cerebral Angiography
0.436695 	 (-): Cerebral Arterial Diseases
0.436695 	 (-): Cerebral Hemorrhage
0.436695 	 (-): Cerebral Revascularization
0.436695 	 (-): Cerebrovascular Circulation
0.436695 	 (-): Chemokines
0.436695 	 (-): Child
0.436695 	 (-): Cholesterol
0.436695 	 (-): Cholesterol, LDL
0.436695 	 (-): Chromosome Mapping
0.436695 	 (-): Citalopram
0.436695 	 (-): Citric Acid
0.436695 	 (-): Clinical Protocols
0.436695 	 (-): Clinical Trials, Phase I as Topic
0.436695 	 (-): Clinical Trials, Phase II as Topic
0.436695 	 (-): Clopidol
0.436695 	 (-): Collagen Type I
0.436695 	 (-): Confounding Factors (Epidemiology)
0.436695 	 (-): Cricetinae
0.436695 	 (-): Crotalid Venoms
0.436695 	 (-): Cyclic AMP
0.436695 	 (-): Cyclic GMP
0.436695 	 (-): Cyclooxygenase 1
0.436695 	 (-): Cyclooxygenase 2
0.436695 	 (-): Cytochrome P-450 CYP1A2
0.436695 	 (-): Cytoplasm
0.436695 	 (-): Cytoplasmic Granules
0.436695 	 (-): Data Collection
0.436695 	 (-): Data Interpretation, Statistical
0.436695 	 (-): Deamino Arginine Vasopressin
0.436695 	 (-): Delayed-Action Preparations
0.436695 	 (-): Depressive Disorder
0.436695 	 (-): Diabetes Mellitus, Type 1
0.436695 	 (-): Diabetic Nephropathies
0.436695 	 (-): Diagnostic Techniques, Cardiovascular
0.436695 	 (-): Dihydropyridines
0.436695 	 (-): Dilatation, Pathologic
0.436695 	 (-): Dipyrone
0.436695 	 (-): Disease Models, Animal
0.436695 	 (-): Drug Administration Routes
0.436695 	 (-): Drug Antagonism
0.436695 	 (-): Drug Delivery Systems
0.436695 	 (-): Drug Incompatibility
0.436695 	 (-): Edetic Acid
0.436695 	 (-): Electrocardiography, Ambulatory
0.436695 	 (-): Embolism, Cholesterol
0.436695 	 (-): Enalapril
0.436695 	 (-): Epitopes
0.436695 	 (-): Equipment Failure
0.436695 	 (-): Equipment Failure Analysis
0.436695 	 (-): Erythrocyte Transfusion
0.436695 	 (-): Erythromycin
0.436695 	 (-): European Continental Ancestry Group
0.436695 	 (-): Exercise
0.436695 	 (-): Exons
0.436695 	 (-): Family Health
0.436695 	 (-): Fatty Acids, Omega-3
0.436695 	 (-): Fish Oils
0.436695 	 (-): Florida
0.436695 	 (-): Fluorescein-5-isothiocyanate
0.436695 	 (-): Free Radicals
0.436695 	 (-): GTP-Binding Protein alpha Subunits, Gi-Go
0.436695 	 (-): Gene Expression Regulation
0.436695 	 (-): Glycemic Index
0.436695 	 (-): Guanine
0.436695 	 (-): Half-Life
0.436695 	 (-): Health
0.436695 	 (-): Heart Defects, Congenital
0.436695 	 (-): Heart Rate
0.436695 	 (-): Heart Septal Defects, Atrial
0.436695 	 (-): Heart Valve Prosthesis
0.436695 	 (-): Heart Valve Prosthesis Implantation
0.436695 	 (-): Hemodynamics
0.436695 	 (-): Heparin, Low-Molecular-Weight
0.436695 	 (-): Hetastarch
0.436695 	 (-): Heterozygote Detection
0.436695 	 (-): Hospitals, University
0.436695 	 (-): Hydrazones
0.436695 	 (-): Hyperemia
0.436695 	 (-): Hypericum
0.436695 	 (-): Hyperlipidemias
0.436695 	 (-): Illinois
0.436695 	 (-): Image Cytometry
0.436695 	 (-): Imidazoles
0.436695 	 (-): Imines
0.436695 	 (-): Infant
0.436695 	 (-): Infant, Newborn
0.436695 	 (-): Infarction, Middle Cerebral Artery
0.436695 	 (-): Inflammation Mediators
0.436695 	 (-): Injections, Subcutaneous
0.436695 	 (-): Insulin Resistance
0.436695 	 (-): Interleukin-10
0.436695 	 (-): Intermittent Claudication
0.436695 	 (-): Intervention Studies
0.436695 	 (-): Intestinal Absorption
0.436695 	 (-): Introns
0.436695 	 (-): Ireland
0.436695 	 (-): Lacerations
0.436695 	 (-): Lateral Ventricles
0.436695 	 (-): Least-Squares Analysis
0.436695 	 (-): Lectins, C-Type
0.436695 	 (-): Leg
0.436695 	 (-): Length of Stay
0.436695 	 (-): Leptin
0.436695 	 (-): Leukocytes, Mononuclear
0.436695 	 (-): Lipids
0.436695 	 (-): Lipoproteins
0.436695 	 (-): Lipoproteins, LDL
0.436695 	 (-): Liver Circulation
0.436695 	 (-): Liver Diseases
0.436695 	 (-): Magnetic Resonance Angiography
0.436695 	 (-): Magnetic Resonance Imaging
0.436695 	 (-): Medication Adherence
0.436695 	 (-): Membrane Glycoproteins
0.436695 	 (-): Metabolic Detoxication, Drug
0.436695 	 (-): Metabolic Syndrome X
0.436695 	 (-): Methacrylates
0.436695 	 (-): Metoprolol
0.436695 	 (-): Mice
0.436695 	 (-): Microscopy, Electron, Scanning
0.436695 	 (-): Models, Cardiovascular
0.436695 	 (-): Monitoring, Intraoperative
0.436695 	 (-): Myocardial Contraction
0.436695 	 (-): Myocardial Perfusion Imaging
0.436695 	 (-): Nadroparin
0.436695 	 (-): Naphthalenes
0.436695 	 (-): Neovascularization, Pathologic
0.436695 	 (-): Neurologic Examination
0.436695 	 (-): New York City
0.436695 	 (-): Nifedipine
0.436695 	 (-): Nitric Oxide
0.436695 	 (-): Nitric Oxide Donors
0.436695 	 (-): Nitroprusside
0.436695 	 (-): Norepinephrine
0.436695 	 (-): Normal Distribution
0.436695 	 (-): Nortriptyline
0.436695 	 (-): Obesity
0.436695 	 (-): Ohio
0.436695 	 (-): Oxidative Stress
0.436695 	 (-): Pain, Postoperative
0.436695 	 (-): Pakistan
0.436695 	 (-): Patient Readmission
0.436695 	 (-): Penile Implantation
0.436695 	 (-): Perioperative Care
0.436695 	 (-): Perioperative Period
0.436695 	 (-): Phenprocoumon
0.436695 	 (-): Phosphatidylserines
0.436695 	 (-): Plasma Substitutes
0.436695 	 (-): Plasminogen Activator Inhibitor 1
0.436695 	 (-): Platelet Factor 4
0.436695 	 (-): Preanesthetic Medication
0.436695 	 (-): Preventive Medicine
0.436695 	 (-): Principal Component Analysis
0.436695 	 (-): Prolactin
0.436695 	 (-): Propensity Score
0.436695 	 (-): Propionates
0.436695 	 (-): Protamines
0.436695 	 (-): Protein Binding
0.436695 	 (-): Protein C
0.436695 	 (-): Protein Precursors
0.436695 	 (-): Publication Bias
0.436695 	 (-): Puerto Rico
0.436695 	 (-): Punctures
0.436695 	 (-): Questionnaires
0.436695 	 (-): Ramipril
0.436695 	 (-): Receptor, Adenosine A2A
0.436695 	 (-): Receptors, Adrenergic, beta-2
0.436695 	 (-): Receptors, Cell Surface
0.436695 	 (-): Receptors, Cytoplasmic and Nuclear
0.436695 	 (-): Receptors, Fibrinogen
0.436695 	 (-): Receptors, G-Protein-Coupled
0.436695 	 (-): Receptors, Thromboxane
0.436695 	 (-): Reference Standards
0.436695 	 (-): Respiration, Artificial
0.436695 	 (-): Reverse Transcriptase Polymerase Chain Reaction
0.436695 	 (-): Russia
0.436695 	 (-): Safety
0.436695 	 (-): Salicylates
0.436695 	 (-): Serbia
0.436695 	 (-): Serotonin Uptake Inhibitors
0.436695 	 (-): Sertraline
0.436695 	 (-): Sex Characteristics
0.436695 	 (-): Shock, Cardiogenic
0.436695 	 (-): Singapore
0.436695 	 (-): Skin
0.436695 	 (-): Splanchnic Circulation
0.436695 	 (-): Statistical Distributions
0.436695 	 (-): Stress, Physiological
0.436695 	 (-): Stroke Volume
0.436695 	 (-): Structure-Activity Relationship
0.436695 	 (-): Substance Withdrawal Syndrome
0.436695 	 (-): Sulfonylurea Compounds
0.436695 	 (-): Superoxides
0.436695 	 (-): Swine
0.436695 	 (-): Thiazolidinediones
0.436695 	 (-): Thienopyridines
0.436695 	 (-): Thionucleotides
0.436695 	 (-): Thrombospondins
0.436695 	 (-): Tissue Fixation
0.436695 	 (-): Tomography, Emission-Computed, Single-Photon
0.436695 	 (-): Tranexamic Acid
0.436695 	 (-): Transcription Factors
0.436695 	 (-): Transfection
0.436695 	 (-): Treatment Refusal
0.436695 	 (-): Tumor Necrosis Factor-alpha
0.436695 	 (-): Vasculitis
0.436695 	 (-): Veins
0.436695 	 (-): Ventricular Dysfunction, Left
0.436695 	 (-): Verapamil
0.436695 	 (-): Weights and Measures
0.436695 	 (-): Withholding Treatment
0.436695 	 (-): World Health
0.436695 	 (-): Wound Healing
0.436695 	 (-): Yohimbine
0.436695 	 (-): alpha 1-Antitrypsin
0.436449 	 (-): Adrenergic alpha-Antagonists
0.436449 	 (-): Adrenergic beta-Antagonists
0.436449 	 (-): Antithrombins
0.436449 	 (-): Blood Pressure
0.436449 	 (-): Breath Tests
0.436449 	 (-): Cardiovascular Surgical Procedures
0.436449 	 (-): Child, Preschool
0.436449 	 (-): Chromatography, Liquid
0.436449 	 (-): Circadian Rhythm
0.436449 	 (-): Clinical Trials, Phase III as Topic
0.436449 	 (-): Depression
0.436449 	 (-): Diagnostic Tests, Routine
0.436449 	 (-): Down-Regulation
0.436449 	 (-): Drugs, Generic
0.436449 	 (-): Endothelial Cells
0.436449 	 (-): Erythropoietin
0.436449 	 (-): Factor VIIa
0.436449 	 (-): Fasting
0.436449 	 (-): Fibrin Fibrinogen Degradation Products
0.436449 	 (-): Fibrinolysis
0.436449 	 (-): Fluorescent Dyes
0.436449 	 (-): Heart-Assist Devices
0.436449 	 (-): Hematologic Tests
0.436449 	 (-): Hemoglobin A, Glycosylated
0.436449 	 (-): Histamine H2 Antagonists
0.436449 	 (-): Hypercholesterolemia
0.436449 	 (-): Hypertension
0.436449 	 (-): Immunoenzyme Techniques
0.436449 	 (-): Insulin
0.436449 	 (-): International Normalized Ratio
0.436449 	 (-): Intracranial Embolism
0.436449 	 (-): Intraoperative Complications
0.436449 	 (-): Kidney Failure, Chronic
0.436449 	 (-): Models, Biological
0.436449 	 (-): Observer Variation
0.436449 	 (-): Perfusion
0.436449 	 (-): Phosphodiesterase Inhibitors
0.436449 	 (-): Placebos
0.436449 	 (-): Platelet Activating Factor
0.436449 	 (-): Platelet Transfusion
0.436449 	 (-): Postoperative Care
0.436449 	 (-): Purinergic P2 Receptor Agonists
0.436449 	 (-): Ranitidine
0.436449 	 (-): Receptor, PAR-1
0.436449 	 (-): Receptors, Adrenergic, alpha-2
0.436449 	 (-): Renal Dialysis
0.436449 	 (-): Rifampin
0.436449 	 (-): Spain
0.436449 	 (-): Stress, Mechanical
0.436449 	 (-): Tablets
0.436449 	 (-): Tablets, Enteric-Coated
0.436449 	 (-): Tandem Mass Spectrometry
0.436449 	 (-): Thromboplastin
0.436449 	 (-): Tomography, X-Ray Computed
0.436449 	 (-): Triglycerides
0.436449 	 (-): United States
0.436449 	 (-): Up-Regulation
0.436449 	 (-): Vascular Diseases
0.436449 	 (-): Warfarin
0.436449 	 (-): beta-Thromboglobulin
0.436203 	 (-): Antithrombin III
0.436203 	 (-): Atherectomy
0.436203 	 (-): Bayes Theorem
0.436203 	 (-): Blood Platelet Disorders
0.436203 	 (-): Calcium Signaling
0.436203 	 (-): Cell Size
0.436203 	 (-): China
0.436203 	 (-): Creatine Kinase
0.436203 	 (-): Databases, Factual
0.436203 	 (-): Endarterectomy, Carotid
0.436203 	 (-): Enoxaparin
0.436203 	 (-): Enzyme Inhibitors
0.436203 	 (-): Evidence-Based Medicine
0.436203 	 (-): Exercise Test
0.436203 	 (-): Hemostasis
0.436203 	 (-): Hypoglycemic Agents
0.436203 	 (-): Intracranial Arteriosclerosis
0.436203 	 (-): Monocytes
0.436203 	 (-): Peptide Hydrolases
0.436203 	 (-): Protein Phosphatase 2
0.436203 	 (-): Protein Tyrosine Phosphatases
0.436203 	 (-): Receptors, Purinergic P2Y1
0.436203 	 (-): Recovery of Function
0.436203 	 (-): Survival Rate
0.436203 	 (-): Therapeutic Equivalency
0.436203 	 (-): Thrombophilia
0.436203 	 (-): Ultrasonography, Doppler, Transcranial
0.436203 	 (-): Vasoconstrictor Agents
0.435956 	 (-): Animals
0.435956 	 (-): Antigens, CD40
0.435956 	 (-): Antigens, CD63
0.435956 	 (-): Antigens, Human Platelet
0.435956 	 (-): Blood Coagulation Factors
0.435956 	 (-): Blood Vessel Prosthesis Implantation
0.435956 	 (-): Calcium
0.435956 	 (-): Cell Adhesion
0.435956 	 (-): Dipyridamole
0.435956 	 (-): Drug Evaluation
0.435956 	 (-): Dual Specificity Phosphatase 2
0.435956 	 (-): Fluorobenzenes
0.435956 	 (-): Hemorheology
0.435956 	 (-): Platelet Membrane Glycoprotein IIb
0.435956 	 (-): Pyrimidines
0.435956 	 (-): Serotonin
0.43571 	 (-): Algorithms
0.43571 	 (-): Cerebral Infarction
0.43571 	 (-): Heart Failure
0.43571 	 (-): Postoperative Hemorrhage
0.43571 	 (-): Pyridines
0.43571 	 (-): Thromboembolism
0.43571 	 (-): Thromboxane B2
0.435463 	 (-): Anticholesteremic Agents
0.435463 	 (-): Calcium Channel Blockers
0.435463 	 (-): Interleukin-6
0.435463 	 (-): Patient Selection
0.435463 	 (-): Postoperative Period
0.435463 	 (-): Prothrombin
0.435463 	 (-): Receptors, Thrombin
0.435463 	 (-): Sex Factors
0.435463 	 (-): Single-Blind Method
0.435216 	 (-): Drug Combinations
0.435216 	 (-): Platelet Adhesiveness
0.434969 	 (-): Antigens, CD
0.434969 	 (-): Cross-Sectional Studies
0.434969 	 (-): Diabetes Mellitus
0.434969 	 (-): Diabetic Angiopathies
0.434969 	 (-): Endothelium, Vascular
0.434969 	 (-): Hirudins
0.434969 	 (-): Pravastatin
0.434722 	 (-): Bleeding Time
0.434722 	 (-): Leukocytes
0.434722 	 (-): Platelet Membrane Glycoproteins
0.434722 	 (-): Simvastatin
0.434475 	 (-): Thrombin
0.434227 	 (-): Recombinant Proteins
0.43398 	 (-): Drug Synergism
0.310429 	 (-): Hydroxymethylglutaryl-CoA Reductase Inhibitors
0.303065 	 (-): Heptanoic Acids
0.303065 	 (-): Pyrroles
0.294475 	 (-): Antibodies, Monoclonal
0.294475 	 (-): Immunoglobulin Fab Fragments
0.289624 	 (-): Peptide Fragments
0.27219 	 (-): Angina, Unstable
0.265173 	 (-): Brain Ischemia
0.265173 	 (-): Fibrinogen
0.25834 	 (-): Anticoagulants
0.248699 	 (-): Adolescent
0.248699 	 (-): CD40 Ligand
0.248699 	 (-): Heparin
0.238941 	 (-): Fibrinolytic Agents
0.215311 	 (-): Blood Coagulation
0.215311 	 (-): Membrane Proteins
0.20081 	 (-): von Willebrand Factor
0.192316 	 (-): Collagen
0.189924 	 (-): Platelet Glycoprotein GPIIb-IIIa Complex
0.186864 	 (-): Case-Control Studies
0.164021 	 (-): Smoking
0.16287 	 (-): Epinephrine
0.16287 	 (-): Peptides
0.16287 	 (-): Postoperative Complications
0.155175 	 (-): Tyrosine
0.144483 	 (+): France
0.140215 	 (-): Statistics, Nonparametric
0.139687 	 (-): Stroke
0.138661 	 (-): P-Selectin
0.120118 	 (-): Young Adult
0.114692 	 (+): Republic of Korea
0.111287 	 (-): Alprostadil
0.111287 	 (-): Analysis of Variance
0.111287 	 (-): Anti-Inflammatory Agents, Non-Steroidal
0.111287 	 (-): Integrin beta3
0.111287 	 (-): Liver
0.111287 	 (-): Statistics as Topic
0.101292 	 (-): Platelet Count
0.099096 	 (-): Cytochrome P-450 Enzyme System
0.099079 	 (-): Drug Interactions
0.093879 	 (-): 2-Pyridinylmethylsulfinylbenzimidazoles
0.093879 	 (-): Premedication
0.093879 	 (-): Research Design
0.093879 	 (-): Severity of Illness Index
0.09359 	 (-): Piperazines
0.091906 	 (-): Biological Markers
0.088721 	 (-): Thiophenes
0.087387 	 (-): Administration, Oral
0.087387 	 (-): C-Reactive Protein
0.083851 	 (-): Diabetes Mellitus, Type 2
0.078128 	 (+): Sirolimus
0.077642 	 (-): Flow Cytometry
0.077275 	 (-): Platelet Activation
0.075582 	 (-): Age Factors
0.075582 	 (-): Angioplasty
0.075582 	 (-): Arterial Occlusive Diseases
0.075582 	 (-): Blood Glucose
0.075582 	 (-): Blood Vessel Prosthesis
0.075582 	 (-): Chronic Disease
0.075582 	 (-): Fatty Acids, Monounsaturated
0.075582 	 (-): Indoles
0.075582 	 (-): Ischemic Attack, Transient
0.075582 	 (-): Patient Compliance
0.075582 	 (-): Sulfonamides
0.075582 	 (-): Vasodilator Agents
0.075136 	 (-): Female
0.070516 	 (-): Coronary Disease
0.066035 	 (-): Cross-Over Studies
0.062122 	 (-): Male
0.061196 	 (-): Reference Values
0.058814 	 (-): Aged
0.054293 	 (-): Adenosine Monophosphate
0.054293 	 (-): Angioplasty, Balloon
0.054293 	 (-): Comorbidity
0.054293 	 (-): Coronary Vessels
0.054293 	 (-): Risk
0.053736 	 (-): Coronary Artery Bypass
0.05175 	 (-): Adult
0.049796 	 (-): Retrospective Studies
0.049783 	 (+): ROC Curve
0.046568 	 (-): Creatine Kinase, MB Form
0.046272 	 (-): Double-Blind Method
0.041024 	 (-): Ticlopidine
0.040424 	 (-): Drug Therapy, Combination
0.035525 	 (-): Middle Aged
0.032847 	 (+): Electrodes
0.032847 	 (+): Mixed Function Oxygenases
0.031154 	 (-): Area Under Curve
0.031154 	 (-): Atrial Fibrillation
0.031154 	 (-): Blood Transfusion
0.031154 	 (-): Body Weight
0.031154 	 (-): Cardiac Surgical Procedures
0.031154 	 (-): Carotid Stenosis
0.031154 	 (-): Cells, Cultured
0.031154 	 (-): Disease Progression
0.031154 	 (-): Endpoint Determination
0.031154 	 (-): Enzyme-Linked Immunosorbent Assay
0.031154 	 (-): Haplotypes
0.031154 	 (-): Hemostatics
0.031154 	 (-): Infusions, Intravenous
0.031154 	 (-): Isoenzymes
0.031154 	 (-): Kinetics
0.031154 	 (-): Leukocyte Count
0.031154 	 (-): Platelet Glycoprotein GPIb-IX Complex
0.031154 	 (-): Thrombolytic Therapy
0.031005 	 (-): Preoperative Care
0.031005 	 (-): Troponin I
0.030854 	 (-): Omeprazole
0.030392 	 (-): Electrocardiography
0.030077 	 (-): Drug Administration Schedule
0.024066 	 (-): Angina Pectoris
0.018271 	 (-): Syndrome
0.014067 	 (-): Peripheral Vascular Diseases
0.013862 	 (-): Cytochrome P-450 CYP3A
0.010488 	 (-): Proton Pump Inhibitors
0.007686 	 (-): Blood Platelets
0.007209 	 (-): Aspirin
0.005489 	 (-): Dose-Response Relationship, Drug
0.005332 	 (-): Myocardial Revascularization
0.005332 	 (-): Prevalence
0.005231 	 (-): Tetrazoles
0.005218 	 (+): Aryl Hydrocarbon Hydroxylases
0.005179 	 (-): Pilot Projects
4.35E-4 	 (-): Platelet Aggregation
0.0 	 (-): Acute Coronary Syndrome
0.0 	 (-): Acute Disease
0.0 	 (+): Adenosine
0.0 	 (-): Adenosine Diphosphate
0.0 	 (-): Aged, 80 and over
0.0 	 (+): Alleles
0.0 	 (-): Amino Acid Substitution
0.0 	 (-): Angioplasty, Balloon, Coronary
0.0 	 (-): Anti-Ulcer Agents
0.0 	 (-): Aprotinin
0.0 	 (-): Apyrase
0.0 	 (-): Arachidonic Acid
0.0 	 (-): Asian Continental Ancestry Group
0.0 	 (-): Biomarkers, Pharmacological
0.0 	 (+): Biotransformation
0.0 	 (-): Blood Coagulation Tests
0.0 	 (-): Blood Loss, Surgical
0.0 	 (-): Blood Proteins
0.0 	 (-): Blood Viscosity
0.0 	 (-): Blotting, Western
0.0 	 (+): Body Mass Index
0.0 	 (-): Cardiac Catheterization
0.0 	 (-): Cardiovascular Agents
0.0 	 (+): Cardiovascular Diseases
0.0 	 (-): Carotid Artery, Internal
0.0 	 (+): Cell Adhesion Molecules
0.0 	 (-): Cerebrovascular Disorders
0.0 	 (-): Chemotherapy, Adjuvant
0.0 	 (+): Chi-Square Distribution
0.0 	 (-): Chromatography, High Pressure Liquid
0.0 	 (-): Clinical Trials as Topic
0.0 	 (-): Cohort Studies
0.0 	 (-): Combined Modality Therapy
0.0 	 (-): Confidence Intervals
0.0 	 (-): Constriction, Pathologic
0.0 	 (-): Coronary Angiography
0.0 	 (-): Coronary Artery Bypass, Off-Pump
0.0 	 (-): Coronary Artery Disease
0.0 	 (-): Coronary Circulation
0.0 	 (-): Coronary Restenosis
0.0 	 (-): Coronary Stenosis
0.0 	 (-): Coronary Thrombosis
0.0 	 (-): DNA
0.0 	 (-): Death
0.0 	 (-): Demography
0.0 	 (-): Diabetes Complications
0.0 	 (-): Drug Monitoring
0.0 	 (-): Drug Resistance
0.0 	 (-): Drug Resistance, Multiple
0.0 	 (-): Drug Tolerance
0.0 	 (+): Drug-Eluting Stents
0.0 	 (-): Electric Impedance
0.0 	 (-): Embolization, Therapeutic
0.0 	 (+): Epidemiologic Methods
0.0 	 (-): Equipment Design
0.0 	 (-): Erythrocyte Deformability
0.0 	 (-): Esomeprazole Sodium
0.0 	 (-): Feasibility Studies
0.0 	 (-): Follow-Up Studies
0.0 	 (-): Gastrointestinal Hemorrhage
0.0 	 (+): Gene Frequency
0.0 	 (-): Genetic Predisposition to Disease
0.0 	 (-): Genetic Variation
0.0 	 (+): Genotype
0.0 	 (-): Germany
0.0 	 (-): Glomerular Filtration Rate
0.0 	 (+): Graft Occlusion, Vascular
0.0 	 (-): Heart Diseases
0.0 	 (-): Hematocrit
0.0 	 (-): Hemoglobins
0.0 	 (-): Hemorrhage
0.0 	 (+): Heterozygote
0.0 	 (+): Homozygote
0.0 	 (-): Humans
0.0 	 (+): Incidence
0.0 	 (-): India
0.0 	 (-): Individualized Medicine
0.0 	 (-): Inflammation
0.0 	 (-): Injections, Intravenous
0.0 	 (-): Integrin alpha2
0.0 	 (-): Intercellular Adhesion Molecule-1
0.0 	 (-): Intracranial Thrombosis
0.0 	 (+): Ischemia
0.0 	 (-): Japan
0.0 	 (+): Kaplan-Meier Estimate
0.0 	 (-): Korea
0.0 	 (-): Linear Models
0.0 	 (-): Linkage Disequilibrium
0.0 	 (-): Logistic Models
0.0 	 (-): Long-Term Care
0.0 	 (+): Microfilament Proteins
0.0 	 (-): Models, Statistical
0.0 	 (-): Monitoring, Physiologic
0.0 	 (+): Multivariate Analysis
0.0 	 (-): Mutation
0.0 	 (-): Mutation, Missense
0.0 	 (-): Myocardial Infarction
0.0 	 (-): Myocardial Ischemia
0.0 	 (-): Myocardium
0.0 	 (-): Necrosis
0.0 	 (-): Nephelometry and Turbidimetry
0.0 	 (+): Odds Ratio
0.0 	 (+): Outcome Assessment (Health Care)
0.0 	 (+): P-Glycoprotein
0.0 	 (+): Pharmacogenetics
0.0 	 (-): Pharmacokinetics
0.0 	 (+): Phenotype
0.0 	 (+): Phosphoproteins
0.0 	 (+): Phosphorylation
0.0 	 (-): Platelet Aggregation Inhibitors
0.0 	 (-): Platelet Function Tests
0.0 	 (-): Platelet-Derived Growth Factor
0.0 	 (-): Platelet-Rich Plasma
0.0 	 (+): Point-of-Care Systems
0.0 	 (+): Polymerase Chain Reaction
0.0 	 (+): Polymorphism, Genetic
0.0 	 (-): Polymorphism, Single Nucleotide
0.0 	 (-): Practice Guidelines as Topic
0.0 	 (+): Predictive Value of Tests
0.0 	 (+): Probability
0.0 	 (-): Prodrugs
0.0 	 (-): Prognosis
0.0 	 (-): Proportional Hazards Models
0.0 	 (-): Prospective Studies
0.0 	 (-): Prosthesis Failure
0.0 	 (-): Prosthesis Implantation
0.0 	 (-): Protein Processing, Post-Translational
0.0 	 (-): Purinergic P2 Receptor Antagonists
0.0 	 (-): Purinergic P2Y Receptor Antagonists
0.0 	 (-): Randomized Controlled Trials as Topic
0.0 	 (-): Reagent Kits, Diagnostic
0.0 	 (-): Receptors, Purinergic P2
0.0 	 (-): Receptors, Purinergic P2Y12
0.0 	 (-): Recurrence
0.0 	 (+): Registries
0.0 	 (-): Regression Analysis
0.0 	 (-): Renal Insufficiency
0.0 	 (+): Reproducibility of Results
0.0 	 (+): Risk Assessment
0.0 	 (+): Risk Factors
0.0 	 (+): Sensitivity and Specificity
0.0 	 (-): Signal Transduction
0.0 	 (-): Stents
0.0 	 (+): Surgical Procedures, Elective
0.0 	 (+): Survival Analysis
0.0 	 (-): Thrombelastography
0.0 	 (-): Thrombosis
0.0 	 (-): Time Factors
0.0 	 (-): Treatment Failure
0.0 	 (-): Treatment Outcome
0.0 	 (-): Troponin
0.0 	 (-): Troponin T
0.0 	 (+): Vasodilation
